GNH USA

Europe — EMA

Nipruss (Sodium Nitroprusside Dihydrate)

GNH USA supplies Nipruss (Sodium nitroprusside), a direct‑acting vasodilator for hypertensive emergencies and controlled hypotension during surgery.

Sodium Nitroprusside Dihydrate

Request sourcing

1
Pack/s

What is Sodium Nitroprusside Dihydrate?

Sodium nitroprusside, the active ingredient in Nipruss, is a direct‑acting vasodilator presented as an intravenous solution for intravenous use. It provides rapid blood pressure reduction and is employed in hypertensive emergencies, controlled hypotension during surgery, acute heart failure, and severe aortic insufficiency.

GNH USA supplies Nipruss as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

What is Sodium Nitroprusside Dihydrate used for?

Nipruss is a direct‑acting vasodilator used in critical cardiovascular conditions.

Hypertensive emergencies: rapid reduction of dangerously elevated blood pressure. Controlled hypotension during surgery: facilitates a predictable low‑pressure field for operative precision. Acute heart failure: decreases afterload and improves cardiac output. Severe aortic insufficiency: lowers regurgitant volume by reducing systemic pressure.

What are the side effects of Sodium Nitroprusside Dihydrate?

Adverse reactions may occur with intravenous sodium nitroprusside therapy.

Common Side Effects: - Headache: transient throbbing sensation during infusion. - Nausea: mild gastrointestinal upset. - Flushing: warm skin sensation, especially on face and neck. - Hypotension: excessive blood pressure drop if dosing exceeds requirement.

Serious or Rare Side Effects: - Cyanide toxicity: accumulation with prolonged high‑dose infusion, presenting as metabolic acidosis. - Methemoglobinemia: oxidation of hemoglobin impairing oxygen delivery. - Arrhythmias: ventricular ectopy or tachyarrhythmias. - Severe hypotension: refractory low blood pressure leading to organ hypoperfusion.

What precautions apply to Sodium Nitroprusside Dihydrate?

Careful monitoring and patient assessment are essential when using Nipruss.

Blood pressure monitoring: continuous invasive measurement required during infusion. Renal function: evaluate before and during therapy due to cyanide clearance dependence. Cyanide risk: limit infusion duration and total dose to reduce toxicity. Concomitant vasodilators: avoid additive hypotensive effects. Pregnancy: use only if potential benefit justifies potential fetal risk. Store at ambient temperature: keep in original container, protect from light and moisture.

What does Sodium Nitroprusside Dihydrate interact with?

Sodium nitroprusside may interact with several drug classes, requiring vigilance.

Major Interactions (Avoid): - Other potent vasodilators (e.g., nitroglycerin, hydralazine): additive hypotension. - Beta‑blockers: may mask reflex tachycardia, complicating hemodynamic assessment. - ACE inhibitors or ARBs: enhanced blood pressure lowering effect.

Moderate Interactions (Monitor Closely): - Diuretics: altered intravascular volume may potentiate hypotension. - Lithium: reduced renal clearance may increase lithium levels. - Anticoagulants: hypotension can exacerbate bleeding risk in vulnerable patients.

Frequently asked questions

What is Nipruss used for?+
Nipruss contains sodium nitroprusside, a direct‑acting vasodilator used in critical care to rapidly lower blood pressure in hypertensive emergencies, to provide controlled hypotension during surgical procedures, and to manage acute heart failure or severe aortic insufficiency by reducing cardiac afterload.
How does sodium nitroprusside work?+
Sodium nitroprusside releases nitric oxide when it enters the bloodstream. The nitric oxide activates guanylate cyclase in vascular smooth muscle, increasing cyclic GMP levels, which cause smooth‑muscle relaxation and prompt dilation of both arteries and veins, leading to a swift fall in systemic vascular resistance.
What is the usual dose of Nipruss?+
The dosing regimen for Nipruss is individualized. A qualified prescriber determines the infusion rate and duration based on the patient’s clinical condition, blood pressure targets, and response to therapy, following established hospital protocols and monitoring guidelines.
Is Nipruss safe during pregnancy or breastfeeding?+
Safety data for sodium nitroprusside in pregnancy and lactation are limited. It should only be used when the potential maternal benefit outweighs any possible risk to the fetus or infant, and the decision must be made by the treating physician.
How do I order Nipruss from GNH USA?+
To request Nipruss, submit an enquiry on the product page at gnh-usa.com, specifying the required quantity. GNH USA works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.
How does Nipruss compare with other vasodilators?+
Compared with agents such as nitroglycerin or hydralazine, sodium nitroprusside offers a more rapid and titratable onset of action, affecting both arterial and venous vessels. This allows precise blood pressure control, but it also carries a higher risk of cyanide accumulation, requiring careful monitoring.
What are the storage and handling requirements for Nipruss?+
Nipruss should be stored at ambient temperature, below 25 °C, in its original sealed container. Protect the solution from direct light, moisture, and extreme temperature fluctuations. Do not freeze or shake the vial before use.
How is Nipruss administered?+
Nipruss is supplied as an intravenous solution and must be administered by slow infusion through a calibrated IV pump or infusion set. Continuous blood pressure monitoring is essential, and the infusion rate is adjusted by the clinician to achieve the desired hemodynamic effect.
What are the most serious risks associated with Nipruss?+
The most serious risks include cyanide toxicity, which can develop with prolonged high‑dose infusions, and severe hypotension leading to organ hypoperfusion. Methemoglobinemia and life‑threatening arrhythmias are also rare but critical complications that require immediate attention.
Who should not receive Nipruss?+
Patients with known hypersensitivity to sodium nitroprusside, those with severe anemia, or individuals with uncontrolled cyanide metabolism disorders should avoid Nipruss. Additionally, it is contraindicated in patients where rapid blood pressure reduction could compromise perfusion to vital organs.
Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.
Send a sourcing enquiry for this product →

Product details

Drug
Sodium Nitroprusside Dihydrate
Route
Intravenous Use
Manufacturer
Oresund Pharma Aps
Origin
EU

Related products

Nipruss

Nipruss

Sodium Nitroprusside Dihydrate

Altamedics Gmbh
EU
Nipruss

Nipruss

Sodium Nitroprusside Dihydrate

Altamedics Gmbh
EU
Nipruss

Nipruss

Sodium Nitroprusside Dihydrate

Oresund Pharma Aps
EU
Nipruss

Nipruss

Sodium Nitroprusside Dihydrate

Altamedics Gmbh
EU